secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rallybio Corp (RLYB)
CIK:        0001739410
Form:       8-K
Filed at:   2025-03-13T23:59:59+00:00
Accession:  0001739410-25-000029
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rallybio Q4 net loss $11M, cash $65.5M; key trial data readouts in 2025
-----------------------------------------------------------------------

- Q4 2024 net loss $11.0M ($0.25/share) vs $20.2M ($0.50/share) in Q4 2023; full-year loss $57.8M.
- Revenue $38k in Q4 2024 from J&J collaboration; zero revenue in year ago period.
- Cash, equivalents, and marketable securities $65.5M as of Dec 31, 2024; runway into 2H 2026.
- RLYB212 Phase 2 sentinel participant dosed; PK/safety data from 2nd trimester expected Q2 2025, at delivery Q3 2025.
- RLYB116 confirmatory PK/PD study to start Q2 2025; Cohorts 1 and 2 data in Q3/Q4 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1739410/000173941025000029/0001739410-25-000029-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1739410/000173941025000029/rlyb-20250313.htm
  HTML page:      https://secwatch.observer/filing/0001739410-25-000029

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer